Galectin Therapeutics Reports Q3 2026 Net Loss of $3.6 Million
Galectin Therapeutics reported a net loss applicable to common stockholders of $3.6 million, or $0.04 per share, for the third quarter of 2026, compared with $8.2 million, or $0.13 per share, a year earlier. Cash and cash equivalents totaled $11.7 million at September 30, 2026, and the company said…